Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials

被引：0
|
作者：
Strain, W. D. [1 ]
Holst, A. G. [2 ]
Rasmussen, S. [2 ]
Saevereid, H. A. [2 ]
James, M. A. [1 ]
机构：
[1] Univ Exeter, Sch Med, Diabet & Vasc Res Ctr, Exeter, Devon, England
[2] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
258
引用
收藏
页码：S130 / S131
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of semaglutide in subjects with type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials
    Desouza, C.
    Garg, S.
    Cariou, B.
    Furberg, J. K.
    Navarria, A.
    Nayak, G.
    Fonseca, V.
    DIABETOLOGIA, 2018, 61 : S369 - S370
  • [22] SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES
    Bellary, S.
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. Gaarsdal
    Leiter, L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 34 : E6 - E7
  • [23] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6
    Seufert, J.
    Desouza, C.
    Kirk, A. R.
    Lawson, J.
    Lingvay, I.
    Sondergaard, A. L.
    Bain, S. C.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 252
  • [24] SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. G.
    Leiter, L. A.
    EUROPEAN HEART JOURNAL, 2017, 38 : 819 - 819
  • [25] SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS REGARDLESS OF METFORMIN USE: A POST HOC EXPLORATORY SUBGROUP ANALYSIS OF SUSTAIN 6 AND PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina
    Rasmussen, Soren
    Bain, Stephen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1604 - 1604
  • [26] Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials
    Yin, Dao-Gen
    Ding, Liang-Liang
    Zhou, Hai-Rong
    Qiu, Mei
    Duan, Xue-Yan
    ENDOCRINE JOURNAL, 2021, 68 (06) : 739 - 742
  • [27] EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER
    Perkovic, Vlado
    Bain, Stephen
    Bakris, George
    Buse, John
    Idorn, Thomas
    Mahaffey, Kenneth
    Marso, Steven
    Nauck, Michael
    Pratley, Richard
    Rasmussen, Soren
    Rossing, Peter
    Tornoe, Karen
    Zinman, Bernard
    Mann, Johannes
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 205 - U715
  • [28] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [29] Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials
    Mellbin, Linda G.
    Bhatt, Deepak L.
    David, Jens-Peter
    Ekstrom, Kathrine
    Petrie, Mark C.
    Rasmussen, Soren
    Vilsboll, Tina
    EUROPEAN HEART JOURNAL, 2024, 45 (15) : 1371 - 1374
  • [30] Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
    Shaman, Ahmed M.
    Bain, Stephen C.
    Bakris, George L.
    Buse, John B.
    Idorn, Thomas
    Mahaffey, Kenneth W.
    Mann, Johannes F. E.
    Nauck, Michael A.
    Rasmussen, Soren
    Rossing, Peter
    Wolthers, Benjamin
    Zinman, Bernard
    Perkovic, Vlado
    CIRCULATION, 2022, 145 (08) : 575 - 585
12345